Pharmacogenetic insights into depression and antidepressant response: Does sex matter?

Current Pharmaceutical Design

Volumn 16, Issue 20, 2010, Pages 2214-2223

  Pitychoutis, P M ^a   Zisaki, A ^a   Dalla, C ^a   Papadopoulou Daifoti, Z ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Gender; Genes; Pharmacogenomics; Polymorphism; Serotonin; SSRI; Stress; Women

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN; SEROTONIN 1A RECEPTOR;

ARTICLE; DEPRESSION; DRUG METABOLISM; DRUG RESPONSE; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; DRUG THERAPY; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954222726     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791792831     Document Type: Article

References (103)

1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52: 1048-60.
2. Nemeroff CB, Bremner JD, Foa EB, et al. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006; 40: 1- 21.
3. Stein MB, Jang KL, Taylor S, et al. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. Am J Psychiatry 2002; 159: 1675-81.
4. Holden C. Sex and the suffering brain. Science 2005; 308: 1574.
5. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003; 74: 5-13.
6. Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry 1997; 58 (Suppl 15): 12-8.
7. Somers JM, Goldner EM, Waraich P, et al. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006; 51: 100-13.
8. Steiner M, Allgulander C, Ravindran A, et al. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. Hum Psychopharmacol 2005; 20: 3-13.
9. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007; 19: 247-55.
10. Uhl K, Parekh A, Kweder S. Females in clinical studies: where are we going? Clin Pharmacol Ther 2007; 81: 600-2.
11. Stewart DE, Ashraf IJ, Munce SE. Women's mental health: a silent cause of mortality and morbidity. Int J Gynaecol Obstet 2006; 94: 343-9.
12. Vigod SN, Stewart DE. Emergent research in the cause of mental illness in women across the lifespan. Curr Opin Psychiatry 2009; 22: 396-400.
13. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38: 82-94.
14. Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009; 3: 257-74.
15. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136-51.
16. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59: 1116-27.
17. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron 2002; 34: 13-25.
18. Dalla C, Antoniou K, Drossopoulou G, et al. Chronic mild stress impact: Are females more vulnerable? Neuroscience 2005; 135: 703-14.
19. Dalla C, Antoniou K, Kokras N, et al. Sex differences in the effects of two stress paradigms on dopaminergic neurotransmission. Physiol Behav 2008; 93: 595-605.
20. Drossopoulou G, Antoniou K, Kitraki E, et al. Sex differences in behavioral, neurochemical and neuroendocrine effects induced by the forced swim test in rats. Neuroscience 2004; 126: 849-57.
21. Pitychoutis PM, Nakamura K, Tsonis PA, et al. Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 2009; 159: 1216-32.
22. Dalla C, Edgecomb C, Whetstone AS, et al. Females do not express learned helplessness like males do. Neuropsychopharmacology 2008; 33: 1559-69.
23. Pitychoutis PM, Griva E, Ioannou K, et al. Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage? Int J Neuropsychopharmacol 2009; 12: 1157-63.
24. Kamper EF, Chatzigeorgiou A, Tsimpoukidi O, et al. Sex differences in oxidant/antioxidant balance under a chronic mild stress regime. Physiol Behav 2009; 98: 215-22.
25. Shors TJ, Mathew J, Sisti HM, et al. Neurogenesis and helplessness are mediated by controllability in males but not in females. Biol Psychiatry 2007; 62: 487-95.
26. Dalla C, Pitychoutis PM, Kokras N, et al. Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol 2010; 106: 226-33.
27. Jansson M, Gatz M, Berg S, et al. Gender differences in heritability of depressive symptoms in the elderly. Psychol Med 2004; 34: 471- 9.
28. Kendler KS, Gatz M, Gardner CO, et al. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006; 163: 109-14.
29. Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl 1): 12-20.
30. Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 2000; 34: 80-8.
31. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002; 162: 18-23.
32. Steimer W, Muller B, Leucht S, et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 2001; 308: 33-41.
33. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003; 160: 1643-50.
34. Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587-95.
35. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009; 76: 215- 28.
36. Schirmer M, Rosenberger A, Klein K, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007; 8: 443-53.
37. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-51.
38. Nakamura M, Ueno S, Sano A, et al. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32-8.
39. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-57.
40. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215- 9.
41. Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003; 66: 1673-80.
42. Yu YW, Tsai SJ, Hong CJ, et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30: 1719-23.
43. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103: 273- 9.
44. Lachman HM, Papolos DF, Saito T, et al. Human catechol-Omethyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-50.
45. Tsai SJ, Gau YT, Hong CJ, et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009; 113: 183-7.
46. Parsey RV, Olvet DM, Oquendo MA, et al. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006; 31: 1745-9.
47. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009; 124: 57-73.
48. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A 1997; 94: 5308-13.
49. Jonsson EG, Norton N, Gustavsson JP, et al. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000; 34: 239-44.
50. Williams RB, Marchuk DA, Gadde KM, et al. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 2003; 28: 533-41.
51. Biver F, Lotstra F, Monclus M, et al. Sex difference in 5HT2 receptor in the living human brain. Neurosci Lett 1996; 204: 25-8.
52. Parsey RV, Oquendo MA, Simpson NR, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res 2002; 954: 173-82.
53. Brummett BH, Siegler IC, McQuoid DR, et al. Associations among the NEO Personality Inventory, Revised and the serotonin transporter gene-linked polymorphic region in elders: effects of depression and gender. Psychiatr Genet 2003; 13: 13-8.
54. Eley TC, Sugden K, Corsico A, et al. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004; 9: 908-15.
55. Flory JD, Manuck SB, Ferrell RE, et al. Neuroticism is not associated with the serotonin transporter (5-HTTLPR) polymorphism. Mol Psychiatry 1999; 4: 93-6.
56. Gonda X, Juhasz G, Laszik A, et al. Subthreshold depression is linked to the functional polymorphism of the 5HT transporter gene. J Affect Disord 2005; 87: 291-7.
57. Grabe HJ, Lange M, Wolff B, et al. Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry 2005; 10: 220-24.
58. Sjoberg RL, Nilsson KW, Nordquist N, et al. Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene. Int J Neuropsychopharmacol 2006; 9: 443-9.
59. Brummett BH, Boyle SH, Siegler IC, et al. Effects of environmental stress and gender on associations among symptoms of depression and the serotonin transporter gene linked polymorphic region (5-HTTLPR). Behav Genet 2008; 38: 34-43.
60. Gotlib IH, Joormann J, Minor KL, et al. HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry 2008; 63: 847-51.
61. Jacobs N, Kenis G, Peeters F, et al. Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006; 63: 989-96.
62. Zalsman G, Huang YY, Oquendo MA, et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006; 163: 1588-93.
63. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9.
64. Baune BT, Hohoff C, Mortensen LS, et al. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect? Depress Anxiety 2008; 25: 920-5.
65. Mizuno T, Aoki M, Shimada Y, et al. Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. J Psychosom Res 2006; 60: 91-7.
66. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 288-95.
67. Gizatullin R, Zaboli G, Jonsson EG, et al. Haplotype analysis reveals tryptophan hydroxylase (TPH) 1 gene variants associated with major depression. Biol Psychiatry 2006; 59: 295-300.
68. Jans LA, Riedel WJ, Markus CR, et al. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007; 12: 522-43.
69. Porter RJ, Mulder RT, Joyce PR, et al. Tryptophan hydroxylase gene (TPH1) and peripheral tryptophan levels in depression. J Affect Disord 2008; 109: 209-12.
70. Schulze TG, Muller DJ, Krauss H, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet 2000; 96: 801-3.
71. Kunugi H, Ishida S, Kato T, et al. A functional polymorphism in the promoter region of monoamine oxidase-A gene and mood disorders. Mol Psychiatry 1999; 4: 393-5.
72. Syagailo YV, Stober G, Grassle M, et al. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am J Med Genet 2001; 105: 168-71.
73. Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 2007; 1122: 130-43.
74. Stein DJ, Daniels WM, Savitz J, et al. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr 2008; 13: 945-9.
75. Shalev I, Lerer E, Israel S, et al. BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. Psychoneuroendocrinology 2009; 34: 382-8.
76. Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010; 15: 260- 71.
77. Lifschytz T, Shalom G, Lerer B, et al. Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats. Eur Neuropsychopharmacol 2006; 16: 115-21.
78. Hodes GE, Hill-Smith TE, Suckow RF, et al. Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther; 332: 266-73.
79. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-52.
80. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 2009; 43: 503-11.
81. Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005; 14: 609-16.
82. Smits KM, Smits LJ, Peeters FP, et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008; 18: 184-90.
83. Perna G, Favaron E, Di Bella D, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005; 30: 2230-5.
84. Gressier F, Bouaziz E, Verstuyft C, et al. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 2009; 19: 195-200.
85. Yu YW, Tsai SJ, Liou YJ, et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006; 16: 498-503.
86. Domschke K, Hohoff C, Mortensen LS, et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 224-8.
87. Cusin C, Serretti A, Zanardi R, et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002; 5: 27-35.
88. Muller DJ, Schulze TG, Macciardi F, et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 2002; 35: 157-8.
89. Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotoninrelated genes in antidepressant response. Mol Psychiatry 2004; 9: 879-89.
90. Tadic A, Muller MJ, Rujescu D, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 325-31.
91. Tadic A, Rujescu D, Muller MJ, et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1370-7.
92. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 781-823.
93. Martin M, Ledent C, Parmentier M, et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002; 159: 379-87.
94. Domschke K, Dannlowski U, Ohrmann P, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008; 18: 751-9.
95. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A 1987; 9: 243-59.
96. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
97. Nutt D. Substance-P antagonists: a new treatment for depression? Lancet 1998; 352: 1644-6.
98. Baghai TC, Schule C, Zill P, et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett 2004; 363: 38-42.
99. Petronis A. Human morbid genetics revisited: relevance of epigenetics. Trends Genet 2001; 17: 142-6.
100. Damberg M. Transcription factor AP-2 and monoaminergic functions in the central nervous system. J Neural Transm 2005; 112: 1281-96.
101. Crowley JJ, Lucki I. Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Curr Pharm Des 2005; 11(2): 157-69.
102. Czlonkowska A, Ciesielska A, Gromadzka G, et al. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr Pharm Des 2005; 11(8): 1017-30.
103. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry-- a useful clinical tool or wishful thinking for the future? Curr Pharm Des 2010; 16(2): 136-44.